Norway· NO-ID_FDEBFB02-FFCC-48CC-9ED0-AB21A845327D
Sylvant
A siltuximab product containing siltuximab, registered in Norway by Recordati Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Siltuximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC11 (siltuximab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Siltuximab · ATC L04AC11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Siltuximab
- Manufacturer
- Recordati Netherlands B.V.
- Country
- Norway (NO)
- ATC code
- L04AC11
- ATC class
- Siltuximab
- Defined daily dose
- 37 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_FDEBFB02-FFCC-48CC-9ED0-AB21A845327D
- no_varenummer161783100NOK 7473.1
- gtin5060146292283
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
151 interactions on record for siltuximab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Siltuximab · interactions on record
151 records
- 28 severe
- 116 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Siltuximab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSYLVANTAbacus Medicine A/S
- SwitzerlandSylvant 100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMedius AG
- CzechiaSYLVANTRecordati Netherlands B.V., Schiphol-Rijk
- SpainSYLVANT 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRecordati Netherlands B.V.
- United KingdomSylvant 100mg powder for concentrate for solution for infusion vialsRecordati UK Ltd
- IrelandSYLVANT 100 mg powder for concentrate for solution for infusionEUSA Pharma (Netherlands) B.V.
- IcelandSylvantRecordati Netherlands B.V.
- PolandSylvantRecordati Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Sylvant
- Liechtenstein · Sylvant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/151ed72e-724b-44ec-b5e3-9f9bd32df86c GET /v1/drugs/151ed72e-724b-44ec-b5e3-9f9bd32df86c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Siltuksimab",
"merkevare_id": "ID_FDEBFB02-FFCC-48CC-9ED0-AB21A845327D",
"name_form_strength": "Sylvant pulv til kons til inf væske, oppl 100 mg",
"prescription_group": "C"
}See everything about siltuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.